Gastric Cancer | Clinical

Nivolumab/Ipilimumab Combo Misses Mark while Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer

September 19, 2021

Data from the phase 3 CheckMate-649 trial showed that the combination therapy of nivolumab and chemotherapy showed a sustained survival benefit in patients with advanced gastric, gastroesophageal junction (GEJ), or esophageal cancer, in contrast to the combination of nivolumab and ipilimumab.